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Abstract: Fractionation of the bioactive extract of a culture of the marine derived actinomycete
Streptomyces cyaneofuscatus M-157 led to the isolation of the known 3-hydroxyquinaldic acid (4),
its amide (5) and three new derivatives (1–3) containing different amino acid residues. The structures
of the new molecules (1–3), including their absolute configuration, were determined by the analysis of
their ESI-TOF MS and one-dimensional (1D) and two-dimensional (2D) NMR spectra and advanced
Marfey’s analysis of their hydrolyzation products. Compound 3 spontaneously dimerized in solution
to give the disulfide derivative 6. Unfortunately, none of the new compounds isolated confirmed the
antimicrobial activity found in the bacterial extract, perhaps indicating that such antibacterial activity
might be due to presence in the extract at the trace level of larger bioactive 3-hydroxyquinaldic acid
derivatives from which compounds 1–3 are biosynthetic precursors. Cytotoxicity tests confirmed the
moderate and weak IC50 values of 15.6 and 51.5 µM for compounds 5 and 1, respectively.
Keywords: 3-hydroxyquinaldic acid; Streptomyces cyaneofuscatus; deep-sea actinobacteria;
Cantabrian Sea
1. Introduction
Marine actinomycetes continue to be the source of new natural products with interesting
bioactive properties. Among them, depsipeptides containing quinaldic acid moieties in their
structures, also called chromodepsipeptides, constitute an interesting structural class due to their
relevant biological activities. These include antibiotics, such as the antibiotics UK-63,052, UK-63,598,
and UK-65,662 [1], and their sulfoxide derivatives RK-1355A and B [2], luzopeptins A–C [3–5],
quinaldopeptin [6] and sandramycin [7,8], or potent cytotoxic agents, such as thiocoraline [9,10] or
the structurally related thiochondrilline C [11]. Most of these compounds act as DNA bisintercalators,
and in the case of thiocoraline, the two 3-hydroxyquinaldic moieties present in the molecule seem to
confer stability to the complex with DNA as part of its mode of action [12].
A recent survey of marine actinomycete strains that were isolated from deep-sea water and
invertebrates (1500–4700 m depth) collected during a cruise expedition to the submarine Avilés
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Canyon, Cantabrian Sea (Biscay Bay, Northeast Atlantic), identified 18 strains having antibiotic
properties against a panel of Gram positive and Gram negative bacteria, including clinical isolates [13].
New natural products with antibiotic and cytotoxic activities were recently uncovered in diverse
Actinobacteria that were isolated from this canyon [14–16]. We report here the discovery of a
family of new compounds from one of these strains, M-157, isolated from a solitary coral belonging
to the order Scleractinia collected at 2000 m depth in this Canyon, identified as Streptomyces
cyaneofuscatus by 16S rDNA. LC-HRMS dereplication [17] of the antimicrobial ethyl acetate extract
of this strain identified the presence of 3-hydroquinaldic acid together with some new structurally
related natural products. Fractionation of this extract using reversed phase flash chromatography and
HPLC yielded 3-hydroxyquinaldic acid, its amide and three new derivatives (1–3) containing different
amino acids as the major components of this extract.
2. Results
2.1. Taxonomy and Phylogenetic Analysis of the Strain M-157
The 16S rDNA of strain M-157 was previously amplified by polymerase chain reaction (PCR) and
sequenced [13]. After Basic Logic Alignment Search Tool (BLAST) sequence comparison, strain M-157
showed 100% identity to S. cyaneofuscatus (Accession number NR_115383); thus, this strain was
designated as S. cyaneofuscatus M-157 (EMBL Sequence number LN824210). The phylogenetic tree that
was generated by neighbour-joining and maximum likelihood method based on 16S rDNA sequence
clearly revealed the evolutionary relationship of strain M-157 with a group of known Streptomyces
species (Figure 1).
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acetate. This extract was fractionated using reversed phase C18 column chromatography followed by 
preparative HPLC to yield compounds 1–3, together with the known compounds 3-hydroxiquinaldic 
acid (4) and its amide (5) (Figure 2), which were identified by ESI-TOF MS and comparison of their 
NMR spectra with those that were described in the literature [18,19]. During the structural 
Figure 1. Neighbour-joining phylogenetic tree obtained by distance matrix analysis of 16S
rDNA sequences, sh w Streptomyces cyane fuscatus M-157 position and most closely related
phylog netic nei hbours. Numbers on branch nodes are bootstrap values (1000 resampli gs;
only values >50% are given). Asterisk indicate th t the corresponding nodes were also recovered in
th maximum likelihood tree. Bar indicates 0.1% sequence diverg nce.
2.2. Isolation and Structural Elucidation of Compounds 1–3
S. cyaneofuscatus M-157 was cultured in solid R5A medium and extracted with acidified ethyl
acetate. This extract was fractionated using reversed phase C18 column chromatography followed by
preparative HPLC to yield compounds 1–3, together with the known compounds 3-hydroxiquinaldic
acid (4) and its amide (5) (Figure 2), which were identified by ESI-TOF MS and comparison of their NMR
spectra with those that were described in the literature [18,19]. During the structural characterization
of compound 3, a spontaneous dimerization through disulphide bond formation in DMSO-d6 solution
led to its full conversion into compound 6.
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Compound 1, is late as a ell a orphous solid, possess a molecular formula of C13H12N2O5,
deduced from the rese ce f a r t ate i at /z 277.0821 i its ESI-T F mass spectrum and 13
signals in its 13C NMR spectru . Absorption axi a at 232, 308, a 360 in its UV spectrum and
signals present in t e ar atic re i f its 1 (δ 8.05 , 7.91 , 7.89 s, 7.66 m, and 7.63 m) and 13C
NMR spectra (δC 153.1, 140.8, 134.6, 131.6, 129.0, 128.9, 127.8, a 126.7), together with the conjugated
carbonyl signal in the latter spectrum at 167.8 pm and a phenol group at δH 12.01 ppm confirmed
the presence of a 3-hydroxyquinaldic moiety. The remai ing signals observed i its 1 and 13C NMR
spectra (Table 1) acc te f r a itr e ated ethine (δH 4.61 ddd, δC 54.6), an oxygenated methylene
(δH 3.98 d and 3.89 dd, 60.8), a car l r ( 171.1), a a i e group (δH 9.19 d), and one
hydroxy group (δH 13. 1 br s), t e l tter r l c rres i t carbox lic acid functionality.
COSY and H BC correlati s ( i r ) ssi t s si ls t t e presence of a serine residue that
was linked to the 3-hydroxyquinaldic moiety through an amide bond between the amino group of
the serine and the carbonyl gr up of 3-hydroxyquinaldic acid, as videnced by HMBC correlations
from th amide NH proton and H-1′ to the carbonyl carbon C-1. Advanced M rfey’s analysis [20]
established the absolute configuration of the serine residu as L after hydrolysis, derivatization with
Nα-(2,4-dinitro-5-fluorophenyl)-L-valinamide (L-FDVA) and LC/MS analysis.
The molecular formula of compound 2 was established as C15H15N3O5, according to the
protonated ion o served at m/z 318.1088 in its ESI-TOF spectrum. Signals with similar chemical
shifts to those of 1 in the aromatic regions of its 1H and 13C NMR spectra and UV absorption
maxima at 232, 308, and 360 nm accounted again for the presence of a 3-hydroxyquinaldic moiety.
The remaining signals that were observed in its NMR spectra were assigned to one nitrogenated
methine (δH 4.53 ddd, δC 52.3), two aliphatic methylenes (δH 2.22 m (2H), δC 31.6, and δH 2.22 m
and 2.11 m, δC 26.5), two carbonyl groups (δC 173.8 and 172.7), and amide NH (δH 9.53 d) and NH2
groups (δH 7.32 br s and 6.80 br s), which together with correlations observed in the COSY and HMBC
spectra (Figure 4) indicated that they belonged to a glutamine (Gln) unit. The structure of compound
2 was finally established as the amide formed between the amino group of Gln and the carboxylate
of 3-hydroxyquinaldic acid through the HMBC correlation observed between the amide NH proton
and the carbonyl carbon C-1 (Figure 4). Hydrolysis in 2 N HCl followed by derivatization with
Nα-(2,4-dinitro-5-fluorophenyl)-L-valinamide (L-FDVA) and LC/MS analysis established the absolute
configuration of the Gln residue present in 2 as L by comparison with glutamic acid standards.
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Table 1. NMR spectroscopic data (DMSO-d6, 500 MHz) for compounds 1 and 2.
Position
1 2
δC, Type δH (J in Hz) δC, Type * δH (J in Hz)
1 167.8, C 168.7, C
2 134.6, C 135.4, C
3 153.1, C 153.4, C
4 120.3, CH 7.89, s 120.4, CH 7.87, s
5 131.6, CH 131.7, CH
6 126.7, CH 7.91, dd (7.6, 1.8) 127.0, CH 7.91, d (7.6, 1.7)
7 128.9, CH
127.8, CH
7.63, m 129.2, CH
128.0, CH
7.65, m
8 7.66, m 7.67, m
9 129.0, CH 8.05, d (8.3) 129.4, CH 8.05, d (8.0)
10 140.8, C 141.2, C
3-OH 12.01, s 12.05, s
1′ 171.1, C 172.7, C
2′ 54.6, CH 4.61, ddd (8.1, 4.2, 3.3) 52.3, CH 4.53, ddd (8.6, 8.0, 3.7)
3′ 60.8, CH2
3.98, dd (11.2, 4.2)
3.89, dd (11.2, 3.3) 26.5, CH2
2.22, m
2.11, m
4′ - - 31.6, CH2 2.22, m, 2H
5′ 173.8, C
NH 9.19, d (8.1) 9.53, d (8.8)
COOH 13.11, br s -
NH2 - 7.32, br s/6.80, br s
* Chemical shifts determined using HSQC and HMBC experiments.
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3-hydroxiquinaldic acid moiety, evidenced by its UV spectrum and NMR signals with chemical shifts
similar to those observed in 1 and 2, the NMR spectra of 3 (Table 2) displayed signals indicative
of the presence of a 2-substituted oxazole-4-carboxylate (δH 8.96 s, δC 159.2, 159.1, 143.6, and 136.2)
and a cysteine residue [δC 172.0 (CO); δH 5.58 m, δC 55.3 (CH); δH 3.08 and 2.96 m, δC 25.6 (CH2);
δH 9.20 (NH)]. Spontaneous conversion of 3 into its dimer 6 was observed in DMSO-d6 solutions
during 2D-NMR acquisition. After complete conversion, the presence of 6 was evidenced by changes
in the cysteine 1H and 13C NMR chemical shifts (Table 2), particularly those of the methylene C-3′’
attached to the sulfur atom, whose 13C signal was highly deshielded from 25.6 in 3 to 39.3 ppm
in 6 due to the formation of the disulfide bridge. COSY and HMBC correlations (Figure 5) that
were observed in the spectra of 6 established the structures of both compounds, the monomer and
the dimer, as depicted in Figure 2. This full conversion was confirmed by ESI-TOF analysis of the
recovered sample, where a protonated ion observed at m/z 717.1057, accounting for a molecular
formula of C32H25N6O10S2, was the unique component detected. This spontaneous dimerization
was further monitored by time-course 1H NMR experiments with a fresh sample of monomer 3
(see Figure S32). Finally, the absolute configuration of the cysteine residue in compound 3 (and therefore
that of the dimeric compound 6) was determined to be L by Marfey’s analysis of the corresponding
cysteic acid derivative [21]. For this purpose, compound 3 was oxidized with performic acid and
the resulting product was hydrolyzed, subsequently derivatized with L-FDVA and then analyzed
by LCMS. Derivatization in parallel of a standard of L-cysteic acid derivatized with both, L and
D-FDVA, provided the L-cysteic-L-FDVA and L-cysteic-D-FDVA (enantiomer of D-cysteic-L-FDVA)
standards that are necessary to perform the Marfey’s analysis.
Table 2. NMR spectroscopic data (DMSO-d6, 500 MHz) for compounds 3 and 6.
Position
3 6
δC, Type * δH (J in Hz) δC, Type * δH (J in Hz)
1 159.1, C 159.1, C
2 134.5, C 134.1, C
3 150.2, C 150.2, C
4 119.8, CH 7.96, br s 119.7, CH 7.92, br s
5 130.4, C 130.4, C
6 127.0, CH 7.89, dd (7.4, 1.8) 127.0, CH 7.89, dd (7.1, 1.6)
7 128.9, CH
128.0, CH
7.59, m 128.9, CH
128.0, CH
7.59, ddd (7.1, 6.8, 1.4)
8 7.63, m 7.62, ddd (8.1, 6.8, 1.6)
9 129.4, CH 8.03, br d (7.8) 129.4, CH 8.00, br d (8.1)
10 142.5, C 142.4, C
3-OH 10.61, s 10.45, s
1′ 159.2, C 159.2, C
2′ 136.2, C 136.0, C
3′ 143.6, CH 8.96, s 143.8, CH 8.90, s
1” 172.0, C 172.0, C
2” 55.3, CH 4.58, m 51.6, CH 4.79, ddd (8.5, 4.5, 4.3)
3” 25.6, CH2
3.08, m
2.96, m 39.3, CH2
3.38, m
3.19, dd (12.6, 4.5)
NH 9.20, d (8.5)
COOH 13.09, br s
* Chemical shifts determined using HSQC and HMBC experiments.
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Compounds 1, 2 and 4–6 were tested against a small panel of pathogenic bacteria, including one
Gram positive (methicillin resistant Staphylococcus aureus, MRSA) and two Gram negative (Escherichia
coli and Acinetobacter baumannii) strains. None of the compounds displayed antimicrobial activity at
the highest concentration tested of 64 µg/mL. Additionally, cytotoxicity tests against the human tumor
cell line HepG2 were also performed. Moderate and weak activities were observed for compounds 5
and 1, with IC50 values of 15.6 and 51.5 µM, respectively. No activity was observed for the rest of the
compounds at the highest concentration tested (20 µg/mL).
3. Discussion
Three new 3-hydroxyquinaldic acid derivatives were isolated from the bioactive extract of S.
cyaneofuscatus M-157. The structure of all the molecules isolated, including their absolute configurations,
were fully established by HRMS, NMR, and Marfey’s analysis. Compound 3 is most probably
biosynthesized from the serine precursor 1 via elongation of the peptidic sequence with a cysteine
residue and post-translational heterocyclization (cylodehydration and dehydrogenation) of the serine
residue onto the carbonyl group of quinaldic acid to form an oxazole ring [22]. Most of the compounds
isolated were tested against a set of pathogenic microorganisms, but none of them displayed the
antimicrobial properties that are found in the crude extract. Additional tests against the human tumor
cell line HepG2 were also performed, indicating moderate and weak activity for compounds 5 and 1,
respectively. Other bioactive compounds with an elongated peptide chain might also be present in trace
amounts in the extract. Interestingly, the three new compounds isolated possess structural features
that are compatible with being biosynthetic precursors of larger chromodepsipeptides, similar to
known antibacterial or cytotoxic agents, such as the luzopeptins, quinaldomycin, sandramycin,
or thiochoraline, whose presence in low amounts in the extract would explain the antimicrobial
properties that were observed.
To prove this hypothesis, experimental evidences of the production of such molecules should
be obtained, perhaps using cultivation-based techniques (OSMAC approaches) to try to maximize the
number of different molecules produced by our microbial strain and eventually trigger the production
in higher amounts of the actual bioactive metabolites [23].
4. Materials and Methods
4.1. General Experimental Procedures
Optical rotations were measured using a Jasco P-2000 polarimeter (JASCO Corporation,
Tokyo, Japan). UV spectra were obtained with an Agilent 1100 DAD (Agilent Technologies, Santa Clara,
CA, USA). IR spectra were recorded on a JASCO FT/IR-4100 spectrometer (JASCO Corporation, Tokyo,
Japan) equipped with a PIKE MIRacleTM single reflection ATR accessory (PIKE Thecnologies Inc.,
Madison, WI, USA). NMR spectra were recorded on a Bruker Avance III spectrometer (500 and
Mar. Drugs 2018, 16, 371 7 of 11
125 MHz for 1H and 13C NMR, respectively) equipped with a 1.7 mm TCI MicroCryoProbeTM (Bruker
Biospin, Falländen, Switzerland). Chemical shifts were reported in ppm while using the signals of
the residual solvent as internal reference (δH 2.50 and δC 39.5 for DMSO-d6). LC–MS and LC–HRMS
analyses were performed, as described previously [24].
4.2. Taxonomic Identification of the Producing Microorganism
Strain S. cyaneofuscatus M-157 was subjected to phylogenetic analysis based on 16S rDNA
sequence analysis [13]. Phylogenetic analysis was performed using MEGA version 6.0 [25]
after multiple alignment of data by Clustal Omega [26]. Distances (distance options according
to the Kimura two-parameter model [27]) and clustering with the neighbour-joining [28] and
maximum likelihood [29] methods were evaluated using bootstrap values that were based on 1000
replications [30].
4.3. Fermentation of the Producing Microorganism
100 petri dishes with R5A solid medium [31] were inoculated with spores of strain M-157.
After three weeks at 28 ◦C, plates were extracted with ethyl acetate under acidic conditions (1%
formic acid). The extract was evaporated to dryness, resuspended in tert-butanol: water (1:1) and
freeze dried.
4.4. Extraction and Bioassay-Guided Isolation
The whole biomass resulting from a 100 Petri dishes culture of strain M-157 was extracted
with ethyl acetate under acidic conditions (1% formic acid). The extract was evaporated to dryness,
resuspended in tert-butanol: water (1:1) and freeze dried. The lyophilized powder (ca. 600 mg)
was disolved in DMSO and injected into a reversed phase column (Phenomenex Sepra™ C18-E
(Phenomenex, Inc., Torrance, CA, USA), 50 µm, 65 Å, 70 g). The column was eluted with a H2O:
CH3CN linear gradient of decreasing polarity (15 mL/min; 20–60% acetonitrile in 42 min with a
final isocratic step of 100% acetonitrile for 15 min), collecting 40 fractions of 15 mL. Fractions were
evaporated to dryness in a centrifugal evaporator and then analyzed by LC/MS to locate the target
3-hydroxyquinaldic derivatives based on their UV and mass spectra.
3-Hydroxy-quinaldic acid (4, 77.0 mg) was identified as the unique component of fractions 10–11
by LC/MS and 1H NMR analysis.
Fractions 16–19 were dissolved in DMSO and purified by reversed-phase preparative HPLC
(Agilent Zorbax SB-C8 PrepHT, 21.2 × 250 mm) eluting with a linear gradient of H2O-0.1% TFA:
CH3CN-0.1% TFA (15 mL/min, 20–32% CH3CN in 40 min), to yield compound 1 (5.1 mg; tR: 24.0 min)
and compound 2 (2.2 mg, tR: 20.4 min).
Fractions 28–31 were dissolved in DMSO and purified by reversed-phase preparative HPLC
(Agilent Zorbax SB-C8 PrepHT, 21.2 × 250 mm) eluting with a linear gradient of H2O-0.1% TFA:
CH3CN-0.1% TFA (15 mL/min, 20–50% CH3CN in 40 min) to yield compound 3 (1.7 mg; tR: 18.9 min)
and the known compound 3-hydroxyquinoline-2-carboxamide (5, 4.2 mg, tR: 20.9 min).
During the structural characterization of compound 3, a spontaneous dimerization through a
disulfide bond formation on standing on DMSO-d6 led to full conversion into compound 6.
Compound 1: yellow solid; [α]20D + 42.9 (c 0.35, MeOH); UV (DAD) λmax 232, 308, 360 nm;
IR (ATR) νmax 3341, 2946, 1660, 1531, 1187, 1138, 1018, 797 cm−1; for 1H and 13C NMR data see Table 1;
(+)-ESI-TOFMS m/z 277.0821 [M + H]+ (calcd. for C13H13N2O5, 277.0824).
Compound 2: yellow solid; [α]20D − 9.6 (c 0.17, MeOH); UV (DAD) λmax 232, sh 308, 360 nm;
IR (ATR) νmax 3343, 2946, 1658, 1532, 1185, 1135, 1019, 721 cm−1; for 1H and 13C NMR data see Table 1;
(+)-ESI-TOFMS m/z 318.1088 [M + H]+ (calcd. for C15H16N3O5, 318.1090).
Compound 3: yellow solid; [α]20D + 3.3 (c 0.47, MeOH); UV (DAD) λmax 230, 260, 308, 360 nm;
IR (ATR) νmax 3371, 2954, 1672, 1452, 1195, 1140, 1019, 845, 800, 724 cm−1; for 1H and 13C NMR data
see Table 2; (+)-ESI-TOFMS m/z 360.0650 [M + H]+ (calcd. for C16H14N3O5S, 360.0654).
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Compound 6: yellow solid; [α]20D − 8.4 (c 0.29, MeOH); UV (DAD) λmax 230, 260, 308, 360 nm;
IR (ATR) νmax 3238, 2954, 2927, 1669, 1515, 1441, 1203, 1140, 840, 723 cm−1; for 1H and 13C NMR data
see Table 2; (+)-ESI-TOFMS m/z 717.1063 [M + H]+ (calcd. for C32H25N6O10S2, 717.1073).
4.5. Hydrolysis and Marfey’s Analysis of Compounds 1 and 2
Samples (300 µg) of compounds 1 and 2 were separately dissolved in 0.6 mL of 6 N HCl and
heated at 110 ◦C for 16 h in a sealed vial. The crude hydrolysates were evaporated to dryness under
a nitrogen stream and each residue was dissolved in 100 µL of water. A 1% (w/v) solution (100 µL)
of L-FDVA (Marfey’s reagent, Nα-(2,4-dinitro-5-fluorophenyl)-L-valinamide) in acetone was added
to an aliquot (50 µL) of a 50 mM solution of each amino acid standard (serine and aspartic acid, D, L,
or DL mixture) and to the aqueous solution of each compound hydrolysate. After addition of 20 µL of
1 M NaHCO3 solution, each mixture was incubated for 60 min at 40 ◦C. The reactions were quenched
by addition of 10 µL of 1 N HCl and the crude mixtures were diluted with 700 µL of acetonitrile and
analyzed by ESI LC/MS on an Agilent 1100 single Quadrupole LC/MS. Separations were carried
out on an Agilent Zorbax SB-C8 column (2.1 × 30 mm, 5 µm), maintained at 40 ◦C. A mixture of
two solvents, A (10% CH3CN, 90% H2O) and B (90% CH3CN, 10% H2O), both containing 1.3 mM
trifluoroacetic acid and 1.3 mM ammonium formate, was used as the mobile phase under a linear
gradient (10–50% B in 6 min) at a flow rate of 0.3 mL/min. Retention times (min) for the derivatized
(L-FDVA) amino acid standards under these chromatographic conditions were as follows: L-Ser: 3.02;
D-Ser: 3.42; L-Glu: 3.33 D-Glu: 3.83. Retention times (min) for the observed peaks in the HPLC trace of
the L-FDVA-derivatized hydrolysis products of compounds 1 and 2, in agreement with the presence of
L-Ser (3.01) in 1 and L-Glu (3.37) in 2.
4.6. Oxidation of Compound 3 with Performic Acid and Marfey’s Analysis
Compound 3 (0.2 mg) was treated with H2O2-HCOOH (1:4) (0.8 mL) at 0 ◦C and the reaction
mixture was allowed to reach room temperature over 2 h. The oxidation of 3 to the corresponding
cysteic acid derivative was confirmed by LC-HRMS (Figures S35 and S36). Solvents were evaporated
to dryness under a N2 stream and the residue was hydrolyzed with 0.6 mL of HCl 6 N at 110 ◦C for
18 h. The hydrolyzed product and the standard amino acid L-cysteic were separately derivatized with
L-FDVA or D-FDVA under an analogous procedure to that used for Marfey’s analysis of compounds
1 and 2. Separations were carried out on a Water Atlantis T3 C18 column (4.6 × 100 mm, 5 µm)
maintained at 40 ◦C. A mixture of water (A) and acetonitrile (B), both containing 0.1% HCOOH,
was used as the mobile phase under a linear gradient (25–30% B in 14 min; then, 100% B) at a flow rate
of 1.0 mL/min. Retention times (min) for the derivatized (L-FDVA or D-FDVA) amino acid standard
L-cysteic acid under these chromatographic conditions were as follows: L-cysteic: 9.38; D-cysteic
(enantiomer of L-cysteic-D-FDVA): 8.51. Retention time (9.56 min) for the peak observed in the HPLC
trace of the L-FDVA-derivatized hydrolysis of the oxidation product of compound 3 was in agreement
with the presence of L-cysteic acid, and therefore with the presence of L-cysteine in compounds 3
and 6.
4.7. Antibacterial Activity Assays
The antibacterial activities of the compounds were evaluated using sequential 2-fold serial
dilutions of each compound in DMSO to provide 10 concentrations starting at 64 µg/mL for all of
the assays. Activity was measured against one Gram-positive (methicillin-resistant S. aureus MB5393)
and two Gram-negative (E. coli MB2884 and A. baumannii MB5973) bacterial strains, as previously
reported [32].
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4.8. Cytotoxicity Assays
Cytotoxic activity against the HepG2 human tumor cell line was tested as previously
described [33], using sequential 2-fold serial dilutions of each compound in DMSO to provide 10
concentrations starting at 20 µg/mL.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/16/10/
371/s1, Figure S1: UV spectrum of compound 1; Figure S2: ESI-TOF spectrum of compound 1; Figure S3: 1H
NMR spectrum (DMSO-d6, 500 MHz) of compound 1; Figure S4: 13C NMR spectrum (DMSO-d6, 125 MHz) of
compound 1; Figure S5: COSY spectrum of compound 1; Figure S6: HSQC spectrum of compound 1; Figure S7:
HMBC spectrum of compound 1; Figure S8: UV spectrum of compound 2; Figure S9: ESI-TOF spectrum of
compound 2; Figure S10: 1H NMR spectrum (DMSO-d6, 500 MHz) of compound 2; Figure S11: COSY spectrum
of compound 2; Figure S12: HSQC spectrum of compound 2; Figure S13: HMBC spectrum of compound 2;
Figure S14: UV spectrum of compound 3; Figure S15: ESI-TOF spectrum of compound 3; Figure S16: 1H NMR
spectrum (DMSO-d6, 500 MHz) of compound 3; Figure S17: COSY spectrum of compound 3; Figure S18: HSQC
spectrum of compound 3; Figure S19: HMBC spectrum of compound 3; Figure S20: UV spectrum of compound 4;
Figure S21: ESI-TOF spectrum of known compound 4; Figure S22: 1H NMR spectrum (CDCl3, 500 MHz) of known
compound 4; Figure S23: UV spectrum of compound 5; Figure S24: ESI-TOF spectrum of known compound 5;
Figure S25: 1H NMR spectrum (DMSO-d6, 500 MHz) of known compound 5; Figure S26: UV spectrum of
compound 6; Figure S27: ESI-TOF spectrum of compound 6; Figure S28: 1H NMR spectrum (DMSO-d6, 500 MHz)
of compound 6; Figure S29: COSY spectrum of compound 6; Figure S30: HSQC spectrum of compound 6;
Figure S31: HMBC spectrum of compound 6; Figure S32: 1H-NMR (DMSO-d6, 500 MHz) time-course conversion
of 3 into 6; Figure S33: HPLC traces of Marfey’s analysis of compound 1; Figure S34: HPLC traces of Marfey’s
analysis of compound 2; Figure S35: LC-HRMS analysis of the oxidation crude of compound 3; Figure S36:
HRMS-MS spectrum of the oxidation product of compound 3; Figure S37: HPLC traces of L- and D-FDVA
derivatives of standard L-cysteic acid; Figure S38: HPLC traces of Marfey’s analysis of the oxidation product of
compound 3.
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